CRSP - TD Cowen cuts CRISPR to underperform cites irrational valuation
2023-12-11 12:11:06 ET
More on CRISPR Therapeutics
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics
- Crispr Therapeutics: The Party Is Over (Rating Downgrade)
- FDA approves Vertex, CRISPR gene therapy for sickle cell disease (update)
- Biotechs post record gains in November amid improving outlook
For further details see:
TD Cowen cuts CRISPR to underperform, cites "irrational" valuation